Randi Grøn
Randi Grøn
Biostatistics Novo Nordisk A/S
Verified email at novonordisk.com
Title
Cited by
Cited by
Year
Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease–a population‐based study
C Jakobsen, J Bartek Jr, V Wewer, I Vind, P Munkholm, R Grøn, ...
Alimentary pharmacology & therapeutics 34 (10), 1217-1224, 2011
1132011
Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL VII randomized …
LK Billings, A Doshi, D Gouet, A Oviedo, HW Rodbard, N Tentolouris, ...
Diabetes Care 41 (5), 1009-1016, 2018
952018
Maternal depression, antidepressant use in pregnancy and Apgar scores in infants
R Gr, Ø Lidegaard, LH Pedersen, PK Andersen, LV Kessing
The British Journal of Psychiatry 202 (5), 347-351, 2013
392013
The effects of maternal depression and use of antidepressants during pregnancy on risk of a child small for gestational age
HM Jensen, R Grøn, Ø Lidegaard, LH Pedersen, PK Andersen, ...
Psychopharmacology 228 (2), 199-205, 2013
292013
Risk factors for venous thromboembolism during pregnancy
TB Jensen, TA Gerds, R Grøn, DM Bretler, MD Schmiegelow, ...
Pharmacoepidemiology and drug safety 22 (12), 1283-1291, 2013
252013
Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b …
VR Aroda, G González-Galvez, R Grøn, N Halladin, M Haluzík, ...
The Lancet Diabetes & Endocrinology 7 (8), 596-605, 2019
182019
Active smoking and risk of breast cancer in a Danish nurse cohort study
ZJ Andersen, JT Jørgensen, R Grøn, EV Brauner, E Lynge
BMC cancer 17 (1), 556, 2017
172017
Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10)
K Brown‐Frandsen, SS Emerson, DK McGuire, TR Pieber, NR Poulter, ...
Diabetes, Obesity and Metabolism 21 (6), 1437-1444, 2019
82019
Nonparametric estimation in an “illness‐death” model when all transition times are interval censored
H Frydman, T Gerds, R Grøn, N Keiding
Biometrical Journal 55 (6), 823-843, 2013
82013
Misspecified poisson regression models for large‐scale registry data: inference for ‘large n and small p
R Grøn, TA Gerds, PK Andersen
Statistics in Medicine 35 (7), 1117-1129, 2016
72016
Binomial regression models
R Grøn, TA Gerds
Handbook of Survival Analysis, 221, 2013
72013
Efficacy and safety of insulin degludec/liraglutide (IDegLira) vs. basal-bolus (BB) therapy in patients with type 2 diabetes (T2D): DUAL VII trial
LK Billings, A Doshi, D Gouet, A Oviedo, HW Rodbard, N Tentolouris, ...
Diabetes 66, A36-A36, 2017
42017
Efficacy of IDegLira vs. Basal–Bolus Therapy in Subjects with Type 2 Diabetes in DUAL VII by Baseline Characteristics
LK Billings, Y Altuntas, DC Klonoff, N Tentolouris, R Grøn, N Halladin, ...
Canadian Journal of Diabetes 42 (5), S47, 2018
32018
Efficacy and safety of insulin degludec/liraglutide (IDegLira) vs basal-bolus therapy in patients with type 2 diabetes: DUAL VII trial
LK Billings, A Doshi, D Gouet, A Oviedo, HW Rodbard, N Tentolouris, ...
Diabetologia 60, S366-S366, 2017
32017
IDegLira improves patient‐reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal–bolus therapy
E Miller, A Doshi, R Grøn, E Jódar, P Őrsy, MF Ranthe, D Sugimoto, ...
Diabetes, Obesity and Metabolism 21 (12), 2643-2650, 2019
22019
IDegLira improves glycaemic control in subjects with type 2 diabetes uncontrolled on basal insulin without deterioration despite discontinuing pre-trial sulphonylurea
A Janez, R Silver, T Vilsboll, R Gron, N Halladin, P Orsy, S Harris
54th EASD Annual Meeting 61 (1), 2018
22018
148-OR: IDegLira Improves Glycemic Control in Japanese Patients with Type 2 Diabetes (T2D) Uncontrolled on Premixed Insulin Therapy
H Watada, BF Agner, A Doshi, R GRØN, MF Ranthe, LK Billings
Diabetes 68 (Supplement 1), 2019
12019
The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII …
LK Billings, BFR Agner, Y Altuntas, R Grøn, N Halladin, DC Klonoff, ...
Journal of Diabetes Science and Technology, 1932296820906888, 2020
2020
DUAL VIII: longer time to intensification with insulin degludec/liraglutide (IDegLira) vs insulin glargine in a 104-week randomised trial mirroring clinical practice
VR Aroda, G Gonzalez-Galvez, M Haluzik, RJ Silver, R Gron, N Halladin, ...
DIABETOLOGIA 62, S95-S96, 2019
2019
147-OR: DUAL VIII: Significantly Longer Time to Treatment Intensification with Insulin Degludec/Liraglutide (IDegLira) vs. Insulin Glargine (IGlar U100) in a 104-Week (Wk …
VR Aroda, G Gonzalez-Galvez, M Haluzik, RJ Silver, R GRØN, N Halladin, ...
Diabetes 68 (Supplement 1), 2019
2019
The system can't perform the operation now. Try again later.
Articles 1–20